2
Registered trials
1
Recruiting
2
Unique sponsors
2
Unique IMPs
1
Commercial trials
Drug classes (ATC)
N
Neurology/Psychiatry (ATC N)
2
Mechanism of action (INN-stem analysis)
Unknown / small molecule
2 substances
Phase II:
1
Phase III/IV:
1
Phase II
1 trial-
EndedDr. Willmar Schwabe GmbH & Co. KG CommercialREFINED AND QUANTIFIED DRY EXTRACT OF GINKGO BILOBA LEAVES (35-67:1) QUANTIFIED TO 22.0 TO 27.0 % OF FLAVONOIDS EXPRESSED AS FLAVONE GLYCOSIDES, 2.8 TO 3.4 % OF GINKGOLIDES A, B AND C, AND 2.6 TO 3.2 % OF BILOBALIDE. EXTRACTION SOLVENT: ACETONE 60% (M/M)
Phase III/IV
1 trial-
RecruitingAmsterdam UMC Stichting AcademicFLUVOXAMINE MALEATE
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| Dr. Willmar Schwabe GmbH & Co. KG | Commercial | 1 | Phase II | 0 |
| Amsterdam UMC Stichting | Academic | 1 | Phase III/IV | 1 |
New trials by year
2025
1
2026
1